Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms SPARTAN
- Sponsors Aragon Pharmaceuticals; Janssen; Janssen Pharmaceutical KK
- 27 Feb 2024 Planned End Date changed from 31 Dec 2026 to 1 Dec 2025.
- 30 Jan 2024 Planned End Date changed from 1 Dec 2026 to 31 Dec 2026.
- 17 Jan 2024 This trial has been completed in Ireland, according to European Clinical Trials Database record.